## Cyclophosphamide-Induced Hemorrhagic Cystitis **Key Point:** Cyclophosphamide causes hemorrhagic cystitis via its metabolite acrolein, not the active alkylating species (phosphoramide mustard). Acrolein is a toxic aldehyde that directly irritates and damages the bladder urothelium. ### Mechanism of Acrolein Toxicity 1. **Hepatic metabolism** produces both phosphoramide mustard (active alkylating agent) and acrolein (toxic byproduct) 2. **Urinary excretion** of acrolein concentrates it in the bladder 3. **Direct mucosal injury** causes inflammation, ulceration, and hemorrhage 4. **Dose-dependent** — risk increases with cumulative dose and high single doses **High-Yield:** Acrolein is a volatile aldehyde that is NOT the alkylating agent; it is a toxic metabolite that causes urinary tract toxicity independent of the drug's chemotherapeutic action. ### Prevention and Management Strategies | Strategy | Mechanism | Effectiveness | |----------|-----------|----------------| | Aggressive hydration | Dilutes acrolein in urine | High | | Frequent voiding | Reduces bladder dwell time | High | | Mesna (2-mercaptoethanesulfonate) | Inactivates acrolein by conjugation | High | | Bladder catheterization | Continuous drainage during infusion | High | **Clinical Pearl:** Mesna is a uroprotective agent that is routinely co-administered with high-dose cyclophosphamide. It works by binding acrolein and rendering it inactive, effectively preventing hemorrhagic cystitis in most patients. **Mnemonic:** **ACR**olein → **A**cute **C**ystitis **R**isk (Acrolein is the culprit, not phosphoramide mustard) ### Why Other Agents Don't Cause This Toxicity - **Melphalan, chlorambucil, busulfan**: Do not produce acrolein as a metabolite; their toxicity profiles differ (bone marrow suppression is dose-limiting) - **Direct-acting agents**: Do not undergo the same hepatic metabolism that generates acrolein
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.